TP53 and cancer: Perhaps unsurprisingly, mutations leading to enhanced anti-apoptotic BCL2 signaling, downregulation of Bax and Bak, and p53 inactivation, promote drug resistance across many cancer types (Supplementary Tables S1 and S2).